The aim of this study was to analyse the combined effect of melanocortin 4 receptor (MC4R) and high mobility group AT-hook 1 (HMGA1) polymorphisms on growth and fatness traits in Duroc pigs. No significant interaction was observed between MC4R and HMGA1 for back-fat traits. An additive mode of inheritance of both gene effects was found for average daily gain and lean meat content. Maximum mean differences from combined genotypic effects were over 2 mm for back fat, 70 g/day for average daily gain and 2% for lean meat content. Therefore, utilization of polymorphisms in both MC4R and HMGA1 for marker-assisted selection could result in an economic benefit to the pig industry.

Objectives: Two historical evidence supported the concept of Gamrosu. The first one was Jeho-tang, a selected thirst quencher in Chosun Dynasty and the second one was Saeng-Maek-san, Dongeuibogam's recommendation as one of the qi-vigorating summer beverages. Gamrosu is a modified fasting therapy beverage which is manufactured from those two prescriptions and the carbohydrates (420.6 kcal/d). A retrospective observational study was conducted to evaluate the clinical outcomes. Methods: Thirty-three cases were reviewed at three local Korean Medical clinics that each site's participant has finished the modified fasting for 10 consecutive days. Clinical outcomes were reviewed at pre-and post-fasting sessions by retrieving the changes of body composition, blood pressure, blood chemistries & urine tests, and subjective symptoms & fatigue scores. Results: Demographics of the observed participants were 17 of male and 16 of female. Post-Gamrosu session, −6.89% of body weight, −8.97% of body fat mass were reduced with the nutrition indices being improved (P＜0.001). −8.72% of systolic blood pressure, −39.86% of serum triglyceride, −6.75% of fast blood sugar and −8.12% of waist circumference were improved (P＜0.05). The levels of high sensitivity C-reactive protein (−58.34%), CRP (−43.55%) and eosinophil (−21.30%) showed the significant diminished profiles (P＜0.05). Liver/kidney functions and the standard of electrolytes were maintained within normal range in stable manners. The fatigue scale scores indicated significant lower scores. Conclusions: Taken together, obesity-related clinical outcomes after a modified fasting therapy with Gamrosu were sufficiently feasible and the observed findings should be considered for further prospective clinical studies.

Gamrosu is a modified fasting therapy beverage (431 kcal/d). A retrospective observational study was conducted to investigate the detoxification feasibility of Gamrosu. Three cases were reviewed which participants have finished the fasting with Garmrosu for 10 consecutive days. Detoxification profiles of Gamrosu were reviewed at pre-and post-fasting sessions. Post-Gamrosu session, −6.3% of average weight, −6.5% of average body fat mass and −6.6% of average muscle mass were reduced with the nutrition indices being improved. The inflammation indices showed the significant diminished profiles. Liver/kidney functions and the standard of electrolytes were maintained within normal range in stable manners, however, marginal elevation of total bilirubin and mild ketoacidosis were observed. The indices of oxidative stress decreased and those of antioxidative activity increased. The fatigue scale scores indicated lower scores except insomnia symptom. Taken together, detoxification profiles of Gamrosu were sufficiently feasible and the observed findings should be considered for further clinical studies.

Gamrosu was originally conceptualized from Jeho-tang, a selected thirst quencher of the kings in Chosun Dynasty and Saeng-Maek-san, a qi-vigorating summer beverage recommended by Dongeuibogam. It is a modified fasting therapy beverage which is manufactured from the single herbal medicines composed of those two prescriptions. This study was conducted on 6 obese patients with hypertension. A modified fasting therapy with Gamrosu was practised on them for 10 consecutive days. After the therapy, their average blood pressures were descended from 148/89 mmHg to 119/79 mmHg. The modified fasting therapy with Gamrosu is supposed to be more effective than general diet program or dietary sodium reduction on controlling hypertension. And, Gamrosu improves anti-hypertensive effect by reducing the side effects, such as fatigue, electrolyte imbalance, heartburn, nausea, and headache, during the modified fasting therapy.